目的 觀察參七腦康膠囊聯(lián)合依達(dá)拉奉注射液治療急性腦梗死的臨床療效。方法 選取2019年3月—2021年3月鄭州人民醫(yī)院收治的100例急性腦梗死住院患者，根據(jù)入院奇偶順序?qū)⒒颊叻譃閷?duì)照組和治療組，每組各50例。對(duì)照組靜脈滴注依達(dá)拉奉注射液，30 mg依達(dá)拉奉注射液用0.9%氯化鈉溶液100 mL稀釋，半小時(shí)內(nèi)滴注結(jié)束，1次/d。治療組在對(duì)照組治療基礎(chǔ)上口服參七腦康膠囊，4粒/次，3次/d。兩組均治療2周。觀察兩組臨床療效，比較兩組治療前后的Barthel指數(shù)評(píng)分量表（ADL）評(píng)分、美國國立衛(wèi)生研究院腦卒中量表（NIHSS）評(píng)分、血液流變學(xué)指標(biāo)、血清因子。結(jié)果 治療后，與對(duì)照組的總有效率78.00%相比，治療組的總有效率94.00%明顯更高（P<0.05）。治療后，兩組患者NIHSS評(píng)分下降，ADL評(píng)分升高（P<0.05），且治療組的NIHSS評(píng)分低于對(duì)照組，ADL評(píng)分高于對(duì)照組（P<0.05）。治療后，兩組患者全血高切黏度（HBV）、纖維蛋白原（FIB）、全血低切黏度（LBV）水平均下降（P<0.05），且治療組的HBV、FIB、LBV水平下降程度相對(duì)對(duì)照組更明顯（P<0.05）。治療后，兩組患者神經(jīng)元特異性烯醇化酶（NSE）、血管內(nèi)皮細(xì)胞生長因子（VEGF）、S-100β水平均下降（P<0.05），且治療組的NSE、VEGF、S-100β水平下降程度相對(duì)對(duì)照組更明顯（P<0.05）。結(jié)論 參七腦康膠囊聯(lián)合依達(dá)拉奉注射液治療急性腦梗死患者可有效減輕神經(jīng)功能損傷，改善患者生活自理能力，同時(shí)調(diào)節(jié)機(jī)體血液流變學(xué)和血清NSE、VEGF、S-100β水平，具有較好的臨床應(yīng)用價(jià)值。

Objective To observe the clinical effect of Shenqi Naokang Capsules combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (100 cases) with acute cerebral infarction in People's Hospital of Zhengzhou from March 2019 to March 2021 were divided into control and treatment groups according to the odd-even order of admission, and each group had 50 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mg added into 0.9% sodium chloride solution, end of infusion within half an hour, once daily. Patients in the treatment group were po administered with Shenqi Naokang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and ADL scores, NIHSS scores, hemorheological indexes, and serum factors level in two groups were compared. Results After treatment, the total effective rate of 94.00% in the treatment group was significantly higher than that of 78.00% in the control group (P < 0.05). After treatment, the NIHSS scores in two groups were decreased, but the ADL scores in two groups were increased (P < 0.05). The NIHSS score in the treatment group was lower than that in the control group, but the ADL score was higher than that in the control group (P < 0.05). After treatment, the levels of HBV, FIB, and LBV in two groups were decreased (P < 0.05), and the levels of HBV, FIB, and LBV in the treatment group was higher than that in the control group (P< 0.05). After treatment, the levels of NSE, VEGF, and S-100β in two groups were decreased (P < 0.05), and the levels of NSE, VEGF, and S-100β in the treatment group was higher than that in the control group (P < 0.05). Conclusion Shenqi Naokang Capsules combined with Edaravone Injection in the treatment of patients with acute cerebral infarction can effectively reduce nerve function injury, improve self-care ability, regulate hemorheology and the levels of NSE, VEGF, and S-100β, which has good clinical application value.

R971

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（LHGJ20200737）